Drug Database
AN

AndroFeme 1 (AndroFeme Cream / AndroFeme 1)

✓ Approved

Lawley Pharmaceuticals · AR · Small Molecule

What is AndroFeme 1?

AndroFeme 1 is a small molecule developed by Lawley Pharmaceuticals. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesAndroFeme Cream, AndroFeme 1
CompanyLawley Pharmaceuticals
Drug ClassSmall Molecule
Molecular TargetAR
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Lawley Pharmaceuticals

Mechanism of Action

Molecular Targets

AndroFeme 1 acts on 1 molecular target:

ARandrogen receptor (DHTR, AR8)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

AndroFeme 1 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersFemale sexual dysfunction✓ Approved

Related Research Articles

PubMedBiotechnology letters2026-09-20

Coupling continuous directed evolution with base editors identifies combinatorial antibiotic resistance.

Wang Hong H, Wang Jiamei J, Zhang Di D, Shang Guangdong G

Antimicrobial resistance (AMR), mainly caused by the mutation of antibiotic resistance genes, poses a great threat to human health. Clinically, TEM-1 β-lactamase encoding blaTEM-1 gene is the most frequently occurred antibiotic resistance gene. Identification, characterization, and monitor of high antibiotic resistance blaTEM-1 mutants are crucial to AMR research and would provide the guidance for the development of next-generation antibiotics. To this end, we report here the adaption of the continuous directed evolution (CDE) along with base editor (BE) gene editing strategy to discover TEM-1 mutants. Firstly, TEM-1 mutants were identified in single-copy bacterial artificial chromosome vector via BE-mediated CDE. Then each mutant genotype was verified in high copy number pUC plasmid. Finally, combinatorial antibiotic resistance was observed when the TEM-1 phenotypes generated in CDE were combined with that of the reported TEM-1 variants. The Escherichia coli strain harboring the vector cloned with 10 TEM-1 mutations showed a minimum inhibitory concentration of 1280 μg/mL to antibiotic cefotaxime, which is the highest data reported thus far. The research highlights the application of gene editing methods to provide insight into the molecular basis of antibiotic resistance.

PMID 42763377
Read full article →
PubMedGenes & diseases2026-09-20

Single-cell sequencing-guided discovery of narciclasine as a dual VCAM-1/ICAM-1 inhibitor for atherosclerosis management.

Wang Yang Y, Cao Zhen Z, Lan Huai H, Li Bo B et al.

Atherosclerosis (AS) remains a leading cause of cardiovascular morbidity and mortality worldwide, with current treatments focused primarily on reducing low-density lipoprotein levels while failing to repair damaged endothelial cells, thus highlighting the urgent need for novel therapeutic drugs. To address this challenge, we analyzed human AS patient single-cell RNA sequencing datasets to identify disease-driving genes and then employed connectivity map analysis to screen for potential therapeutic compounds. Using network pharmacology and machine learning to predict core drug targets, the study validated drug-target interactions through molecular docking, molecular dynamics simulations, and surface plasmon resonance analysis, with experimental validation conducted using endothelial cell damage models and ApoE -/- atherosclerotic mice. The integrative approach successfully identified narciclasine as a promising therapeutic compound that targets vascular cell adhesion molecule 1 and intercellular adhesion molecule-1 (VCAM-1/ICAM-1) for AS treatment, with molecular studies confirming strong binding affinity and experimental validation demonstrating significant alleviation of endothelial dysfunction through downregulation of VCAM-1/ICAM-1 expression and reduction of aortic plaque burden in mouse models. This multiplatform methodology combining single-cell sequencing, network pharmacology, machine learning, computational simulation, and experimental validation provides a robust framework for drug discovery while positioning narciclasine as a promising therapeutic candidate warranting clinical investigation for AS treatment.

PMID 42763524
Read full article →
PubMedCureus2026-09-20

Quality Assessment of an Immunotherapy Toxicity Clinic: A Clinical Audit at Castle Hill Hospital Evaluating Adherence to Clinical Guidelines, Documentation Standards, and Clinical Outcomes.

Hussein Ahmed A

Immunotherapy has developed as a cancer treatment by enhancing the body's immune system to attack cancer cells. Checkpoint inhibitors (e.g., programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte antigen-4 (CTLA-4)) have shown very good outcomes in treating several tumour types. However, their use can cause a unique category of toxicities, immune-related adverse events (irAEs). These differ from chemotherapy-related side effects, may affect any organ, and require specialised recognition and management. This audit reviews the performance of a dedicated Immunotherapy Toxicity Clinic at Queen's Centre for Oncology and Haematology, Hull University Teaching Hospitals. It includes all oncology patients referred between January 1 and June 30, 2024. Using a validated clinical tool, we assess the types, severity, and outcomes of irAEs, as well as adherence to protocols and quality of documentation. This work highlights current practice, identifies gaps, and provides a quality improvement tool for managing patients on immunotherapy.

PMID 42763605
Read full article →
PubMedAmerican journal of lifestyle medicine2026-09-20

Implementing 1:1 Lifestyle Medicine Coaching Visits for Management of Uncontrolled Type 2 Diabetes: Cone Health Reidsville Endocrinology.

Wang David D, Nida Gebreselassie G, Hardesty Valerie V, Staffier Kara L KL

Lifestyle medicine (LM) provides a high-value framework for treating and potentially reversing chronic diseases, such as type 2 diabetes (T2D), obesity, cardiovascular diseases, and some cancers. Yet, the field of LM is still growing, and few examples exist of how to successfully implement LM into clinical care. This paper describes the implementation of 1:1 lifestyle medicine (LM) coaching visits for 45 patients with uncontrolled type 2 diabetes (T2D), (mean HbA1c 10.5%) and on multiple diabetes medications, at Cone Health's Reidsville Endocrinology practice in North Carolina, USA. In brief, during routine endocrinology visits, the lead physician of the LM program at Cone Health, who is trained in LM, identified patients with uncontrolled T2D where scheduling allowed him to fit in some additional time for coaching. Forty-five interested patients selected over a period of several weeks from Spring of 2022 to Fall of 2022 made the first cohort. During a typical LM encounter, immediately after addressing their referral concerns with a routine endocrinology consult, verbally consenting patients were personally invited to learn more about LM. They were provided with a packet of materials focused predominately on prescribing nutrition and exercise as treatment for chronic disease. The physician spent an additional 10-15 minutes with each verbally consenting patient to go through selected materials in the packet, focusing largely on nutrition and physical activity, and successfully billed for the additional time. The patients were encouraged to take the packet home for further learning and return to their next routine visits with questions and to engage in further coaching. Following this brief but intensely focused coaching session which was done in addition to the routine endocrinology visit, lifestyle medicine coaching was able to be incorporated into subsequent, routine endocrinology visits in many of the initially identified patients. The majority of these patients also accepted a referral to a dietitian in the same practice. This experience highlights a model for potentially integrating LM coaching into routine practice and, consistent with previous research, highlights the importance of a site champion for successful LM implementation. Future research is needed to formally assess the success of coaching visits, particularly in terms of assessing health outcomes in patients who engaged in the 1:1 coaching.

PMID 42763494
Read full article →
PubMedDiabetes, metabolic syndrome and obesity : targets and therapy2026-09-20

Reply to Comment on "Prevalence and Correlates of Sleep Problems in Children and Adolescents with Type 1 Diabetes: A Cross-Sectional Study" [Response to Letter].

Alqahtani Youssef A YA, Shati Ayed A AA, Mahmood Syed Esam SE

PMID 42763738
Read full article →
PubMedIranian journal of pharmaceutical research : IJPR2026-09-20

Binding of Epimedium Flavonoids to Human Serum Albumin: Insights from Spectroscopic and Molecular Docking Studies.

Wang Na N, Wang Yuwei Y, Yang Yang Y, Dong Lele L et al.

Epimedin A (EA), epimedin B (EB), and epimedin C (EC), major bioactive flavonoids in Epimedium Herba, have diverse pharmacological activities; however, their interactions with human serum albumin (HSA) remain unclear. This study aimed to investigate the binding mechanisms of EA, EB, and EC to HSA. Multispectroscopic techniques, including UV-vis, fluorescence, and synchronous fluorescence spectroscopy, as well as molecular docking and dynamics simulations, were employed under simulated physiological conditions. Fluorescence spectra were recorded at 298, 303, and 310 K, and molecular docking was performed with HSA (PDB ID: 1BKE). All three flavonoids quenched the intrinsic fluorescence of HSA via static quenching, forming 1:1 complexes with binding constants greater than 104 L·mol-1 (EB > EA > EC at 298 K). Thermodynamic analysis indicated spontaneous binding driven by hydrogen bonds and van der Waals forces. Synchronous fluorescence showed no significant microenvironmental changes around Trp and Tyr residues. Molecular docking and dynamics simulations suggested ligand-dependent differences in the preferred binding regions of HSA. These findings provide preliminary in vitro evidence for the binding of epimedin flavonoids to HSA and may inform future pharmacokinetic investigations.

PMID 42763635
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about AndroFeme 1